1. ZHAW digitalcollection
  2. Life Sciences und Facility Management
  3. Publikationen
  4. Publikationen Life Sciences und Facility Management
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbu Eid, Sameer-
dc.contributor.authorAdams, Michael-
dc.contributor.authorScherer, Thomas-
dc.contributor.authorTorres-Gómez, Héctor Manuel-
dc.contributor.authorHackl, Martina Theresa-
dc.contributor.authorKaplanian, Mairam-
dc.contributor.authorRiedl, Rainer-
dc.contributor.authorLuger, Anton-
dc.contributor.authorFürnsinn, Clemens-
dc.date.accessioned2018-02-14T07:55:38Z-
dc.date.available2018-02-14T07:55:38Z-
dc.date.issued2017-
dc.identifier.issn0014-2999de_CH
dc.identifier.issn1879-0712de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/2761-
dc.description.abstractEmodin is found in remedies from Traditional Chinese Medicine. Since antihyperglycaemic action was observed in rodents, non-scientific sources advertise emodin intake as a natural cure for diabetes. Emodin was admixed to high fat-food of obese mice at two doses (2 and 5 g/kg; daily emodin uptake 103 and 229 mg/kg). Comparison was made to ad libitum fed and to food restricted control groups, the latter showing the same weight gain as the corresponding emodin-treated groups. Emodin blunted food intake by 6% and 20% for the low and high dose, which was accompanied by proportionate reductions in weight gain. Emodin reduced blood glucose relative to freely feeding controls, but comparison to weight-matched controls unmasked deterioration, rather than improvement, of basal glycaemia (mmol/l: fed ad libitum, 9.5±0.4; low emodin, 9.4±0.3, weight-matched, 8.2±0.3; high emodin, 7.2±0.4, weight-matched, 6.1±0.3; P<0.01, emodin vs weight-matched) and glucose tolerance (area under the curve, min*mol/l: fed ad libitum, 2.01±0.08; low emodin, 1.97±0.12, weight-matched, 1.75±0.03; high emodin, 1.89±0.07, weight-matched, 1.65±0.05; P<0.0002, emodin vs weight-matched). An insulin tolerance test suggested insulin desensitisation by prolonged emodin treatment. Furthermore, a single oral emodin dose did not affect glucose tolerance in obese mice, whereas intravenous injection in rats suggested a potential of emodin to acutely impair insulin release. Our results show that the antihyperglycaemic action of emodin as well as associated biochemical alterations could be the mere consequences of a spoilt appetite. Published claims of antidiabetic potential via other mechanisms evoke the danger of misuse of natural remedies by diabetic patients.de_CH
dc.language.isoende_CH
dc.publisherElsevierde_CH
dc.relation.ispartofEuropean Journal of Pharmacologyde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectGlucosede_CH
dc.subjectEmodinde_CH
dc.subjectDiabetesde_CH
dc.subject.ddc572: Biochemiede_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.titleEmodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodentsde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementLife Sciences und Facility Managementde_CH
zhaw.organisationalunitInstitut für Chemie und Biotechnologie (ICBT)de_CH
dc.identifier.doi10.1016/j.ejphar.2017.01.022de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end84de_CH
zhaw.pages.start77de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume798de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedCC Drug Discoveryde_CH
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
There are no files associated with this item.
Show simple item record
Abu Eid, S., Adams, M., Scherer, T., Torres-Gómez, H. M., Hackl, M. T., Kaplanian, M., Riedl, R., Luger, A., & Fürnsinn, C. (2017). Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents. European Journal of Pharmacology, 798, 77–84. https://doi.org/10.1016/j.ejphar.2017.01.022
Abu Eid, S. et al. (2017) ‘Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents’, European Journal of Pharmacology, 798, pp. 77–84. Available at: https://doi.org/10.1016/j.ejphar.2017.01.022.
S. Abu Eid et al., “Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents,” European Journal of Pharmacology, vol. 798, pp. 77–84, 2017, doi: 10.1016/j.ejphar.2017.01.022.
ABU EID, Sameer, Michael ADAMS, Thomas SCHERER, Héctor Manuel TORRES-GÓMEZ, Martina Theresa HACKL, Mairam KAPLANIAN, Rainer RIEDL, Anton LUGER und Clemens FÜRNSINN, 2017. Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents. European Journal of Pharmacology. 2017. Bd. 798, S. 77–84. DOI 10.1016/j.ejphar.2017.01.022
Abu Eid, Sameer, Michael Adams, Thomas Scherer, Héctor Manuel Torres-Gómez, Martina Theresa Hackl, Mairam Kaplanian, Rainer Riedl, Anton Luger, and Clemens Fürnsinn. 2017. “Emodin : A Compound with Putative Antidiabetic Potential, Deteriorates Glucose Tolerance in Rodents.” European Journal of Pharmacology 798: 77–84. https://doi.org/10.1016/j.ejphar.2017.01.022.
Abu Eid, Sameer, et al. “Emodin : A Compound with Putative Antidiabetic Potential, Deteriorates Glucose Tolerance in Rodents.” European Journal of Pharmacology, vol. 798, 2017, pp. 77–84, https://doi.org/10.1016/j.ejphar.2017.01.022.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.